• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丙二酸1,3 - 二硫醇 - 2 - 亚基二异丙酯对大鼠肝脏微粒体电子传递系统的影响。

Effect of diisopropyl 1,3-dithiol-2-ylidenemalonate on microsomal electron transport system in rat liver.

作者信息

Katoh M, Kitada M, Satoh T, Kitagawa H, Sugimoto T, Kasai T

出版信息

J Pharmacobiodyn. 1980 May;3(5):261-3. doi: 10.1248/bpb1978.3.261.

DOI:10.1248/bpb1978.3.261
PMID:7411388
Abstract

Effect of diisopropyl 1,3-dithiol-2-ylidenemalonate (NKK-105) on the components of rat liver microsomal electron transport system was investigated by comparison with those of phenobarbital, 3-methylcholanthrene and polychlorinated biphenyl. When NKK-105 was administered to rats at a dose of 250 mg/kg/day for 7 days, cytochrome b5 content and NADPH-cytochrome c reductase activity were significantly increased but cytochrome P-450 content to the lesser extent. Three inducers of the drug metabolizing enzymes remarkably increased cytochrome P-450 content but increased cytochrome b5 content to a lesser extent.

摘要

通过与苯巴比妥、3-甲基胆蒽和多氯联苯相比较,研究了丙二酸1,3-二硫代-2-亚丙酯(NKK-105)对大鼠肝脏微粒体电子传递系统各组分的影响。当以250mg/kg/天的剂量给大鼠施用NKK-105,持续7天时,细胞色素b5含量和NADPH-细胞色素c还原酶活性显著增加,但细胞色素P-450含量增加程度较小。三种药物代谢酶诱导剂显著增加细胞色素P-450含量,但细胞色素b5含量增加程度较小。

相似文献

1
Effect of diisopropyl 1,3-dithiol-2-ylidenemalonate on microsomal electron transport system in rat liver.丙二酸1,3 - 二硫醇 - 2 - 亚基二异丙酯对大鼠肝脏微粒体电子传递系统的影响。
J Pharmacobiodyn. 1980 May;3(5):261-3. doi: 10.1248/bpb1978.3.261.
2
Stimulatory effect of cytochrome b5 induced by p-nitroanisole and diisopropyl 1,3-dithiol-2-ylidenemalonate on rat liver microsomal drug hydroxylations.对硝基苯甲醚和丙二酸1,3 -二硫醇-2 -亚异丙酯诱导的细胞色素b5对大鼠肝脏微粒体药物羟化作用的刺激效应
J Biochem. 1982 Jul;92(1):305-13. doi: 10.1093/oxfordjournals.jbchem.a133927.
3
Further studies on the in vivo effect of diisopropyl 1,3-dithiol-2-ylidenemalonate (NKK-105) on the liver microsomal drug oxidation system in rats.
Biochem Pharmacol. 1981 Oct;30(20):2759-65. doi: 10.1016/0006-2952(81)90412-3.
4
Effect of malotilate (diisopropyl 1,3-dithiol-2-ylidenemalonate) on drug metabolizing activity in rat liver microsomes.
Jpn J Pharmacol. 1987 Jul;44(3):303-10. doi: 10.1254/jjp.44.303.
5
[Effects of diispropyl 1, 3-dithiol-2-ylidene malonate (NKK-105) on the drug-metabolizing enzymes and fine structure of rat liver (author's transl)].丙二酸二异丙酯-1,3-二硫醇-2-亚基(NKK-105)对大鼠肝脏药物代谢酶及超微结构的影响(作者译)
Nihon Yakurigaku Zasshi. 1979 Sep;75(6):571-84.
6
Effect of diisopropyl 1,3-dithiol-2-ylidenemalonate (NKK-105) on fatty liver induced by carbon tetrachloride.丙二酸二异丙酯-1,3-二硫醇-2-亚基(NKK-105)对四氯化碳诱导的脂肪肝的影响。
Jpn J Pharmacol. 1981 Feb;31(1):15-21. doi: 10.1254/jjp.31.15.
7
Effect of diisopropyl 1,3-dithiol-2-ylidenemalonate (NKK-105) and phenobarbital on fatty acid composition of liver microsomes.丙二酸二异丙酯-1,3-二硫醇-2-亚基(NKK-105)和苯巴比妥对肝脏微粒体脂肪酸组成的影响。
Med J Osaka Univ. 1983 Mar;33(3-4):41-7.
8
Protective effects of diisopropyl 1, 3-dithiol-2-ylidene malonate (NKK-105) on liver injury by carbon tetrachloride (CCl4).丙二酸二异丙酯-1,3-二硫醇-2-亚基(NKK-105)对四氯化碳(CCl₄)所致肝损伤的保护作用
J Toxicol Sci. 1982 Feb;7(1):13-8. doi: 10.2131/jts.7.13.
9
Modulation of the reductive metabolism of halothane by microsomal cytochrome b5 in rat liver.
Biochim Biophys Acta. 1987 Dec 7;926(3):231-8. doi: 10.1016/0304-4165(87)90208-x.
10
[Induced modification of liver NADPH-cytochrome P-450 activity and II microsomal electron transport chain as a function of age in rats].
Postepy Hig Med Dosw. 1994;48(5):631-44.

引用本文的文献

1
Hepatoprotection by malotilate against carbon tetrachloride-alcohol-induced liver fibrosis.马洛替酯对四氯化碳-酒精诱导的肝纤维化的肝保护作用。
Agents Actions. 1986 Aug;18(5-6):600-3. doi: 10.1007/BF01964970.
2
Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
Eur J Clin Pharmacol. 1986;30(4):407-16. doi: 10.1007/BF00607952.